Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileRobert Carl Stanton, M.D.

TitleAssociate Professor of Medicine
InstitutionJoslin Diabetes Center
DepartmentMedicine
AddressJoslin Diabetes Center
Renal Section
One Joslin Place
Boston MA 02215
Phone617/732-2477
Fax617/732-2467
vCardDownload vCard (login for email)

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01DK054380     (STANTON, ROBERT CARL)Feb 1, 2000 - May 31, 2010
NIH/NIDDK
Glucose 6-P Dehydrogenase and Diabetic Complications
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017 Nov; 19(11):1610-1619. PMID: 28636754.
    View in: PubMed
  2. Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, Yorek MA, Wu IH, Lockhart S, Coppey LJ, Pfenninger A, Liew CW, Qiang G, Burkart AM, Hastings S, Pober D, Cahill C, Niewczas MA, Israelsen WJ, Tinsley L, Stillman IE, Amenta PS, Feener EP, Vander Heiden MG, Stanton RC, King GL. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med. 2017 Jun; 23(6):753-762. PMID: 28436957.
    View in: PubMed
  3. Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 2017 Jul; 92(1):258-266. PMID: 28396115.
    View in: PubMed
  4. Chen J, Fan F, Wang JY, Long Y, Gao CL, Stanton RC, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017 Mar 09; 7:44128. PMID: 28276512.
    View in: PubMed
  5. Spencer NY, Stanton RC. Glucose 6-phosphate dehydrogenase and the kidney. Curr Opin Nephrol Hypertens. 2017 Jan; 26(1):43-49. PMID: 27755120.
    View in: PubMed
  6. Skupien J, Warram JH, Smiles AM, Stanton RC, Krolewski AS. Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. Diabetes Care. 2016 Dec; 39(12):2262-2269. PMID: 27647852.
    View in: PubMed
  7. Liu W, Yang Y, Liu Y, Lu X, Guo S, Wu M, Wang M, Yan L, Wang Q, Zhao X, Tong X, Hu J, Li Y, Hu R, Stanton RC, Zhang Z. Exogenous kallikrein protects against diabetic nephropathy. Kidney Int. 2016 Nov; 90(5):1023-1036. PMID: 27546607.
    View in: PubMed
  8. Stanton RC. In Reply to 'Restricting Metformin in CKD: Continued Caution Warranted'. Am J Kidney Dis. 2015 Dec; 66(6):1102. PMID: 26593315.
    View in: PubMed
  9. Stanton RC. Diabetic Kidney Disease and Hypertension. Exp Clin Endocrinol Diabetes. 2016 Feb; 124(2):93-8. PMID: 26575123.
    View in: PubMed
  10. Spencer NY, Yan Z, Cong L, Zhang Y, Engelhardt JF, Stanton RC. Definitive localization of intracellular proteins: Novel approach using CRISPR-Cas9 genome editing, with glucose 6-phosphate dehydrogenase as a model. Anal Biochem. 2016 Feb 01; 494:55-67. PMID: 26576833; PMCID: PMC4695245 [Available on 02/01/17].
  11. Stanton RC. Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations? Am J Kidney Dis. 2015 Aug; 66(2):193-5. PMID: 25960301.
    View in: PubMed
  12. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, Stanton RC, Dodds ED, Powers R, Franco R. Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol. 2014 Sep 19; 9(9):2032-48. PMID: 24937102; PMCID: PMC4168797.
  13. Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 2014 Dec; 25(12):2916-25. PMID: 24904086; PMCID: PMC4243344.
  14. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014 Feb; 63(2 Suppl 2):S3-21. PMID: 24461728.
    View in: PubMed
  15. Stanton RC. Frontiers in diabetic kidney disease: introduction. Am J Kidney Dis. 2014 Feb; 63(2 Suppl 2):S1-2. PMID: 24461726.
    View in: PubMed
  16. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014 Feb 04; 129(5):542-4. PMID: 24334174.
    View in: PubMed
  17. Roshan B, Stanton RC. A story of microalbuminuria and diabetic nephropathy. J Nephropathol. 2013 Oct; 2(4):234-40. PMID: 24475455; PMCID: PMC3891126.
  18. Stanton RC. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease. Curr Diab Rep. 2013 Aug; 13(4):567-73. PMID: 23653011.
    View in: PubMed
  19. Zhang Z, Yang Z, Zhu B, Hu J, Liew CW, Zhang Y, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Increasing glucose 6-phosphate dehydrogenase activity restores redox balance in vascular endothelial cells exposed to high glucose. PLoS One. 2012; 7(11):e49128. PMID: 23185302; PMCID: PMC3501497.
  20. Stanton R, Sciabola S, Salatto C, Weng Y, Moshinsky D, Little J, Walters E, Kreeger J, DiMattia D, Chen T, Clark T, Liu M, Qian J, Roy M, Dullea R. Chemical modification study of antisense gapmers. Nucleic Acid Ther. 2012 Oct; 22(5):344-59. PMID: 22852836.
    View in: PubMed
  21. Krolewski AS, Warram JH, Forsblom C, Smiles AM, Thorn L, Skupien J, Harjutsalo V, Stanton R, Eckfeldt JH, Inker LA, Groop PH. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 2012 Nov; 35(11):2311-6. PMID: 22851596; PMCID: PMC3476893.
  22. Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012 Sep; 82(5):589-97. PMID: 22622493; PMCID: PMC3425658.
  23. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 2012 May; 64(5):362-9. PMID: 22431005; PMCID: PMC3325335.
  24. Stanton RC. Oxidative stress and diabetic kidney disease. Curr Diab Rep. 2011 Aug; 11(4):330-6. PMID: 21557044.
    View in: PubMed
  25. Stanton RC. Comment on: Ferrannini. Learning from glycosuria. Diabetes 2011;60:695-696. Diabetes. 2011 Jul; 60(7):e19; author reply e20. PMID: 21709275; PMCID: PMC3121419.
  26. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011 Mar; 22(3):545-53. PMID: 21355053; PMCID: PMC3060448.
  27. Stanton RC, King GL. A complex interplay of factors causes diabetic nephropathy. Metabolism. 2011 May; 60(5):591-3. PMID: 21109270.
    View in: PubMed
  28. Stanton RC. Use of medications to lower urine protein level in patients with diabetic kidney disease. Curr Diab Rep. 2010 Aug; 10(4):257-60. PMID: 20532702.
    View in: PubMed
  29. Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010 Jun; 33(6):1337-43. PMID: 20332356; PMCID: PMC2875450.
  30. Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, Guo L, Kulkarni RN, Loscalzo J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2010 May; 24(5):1497-505. PMID: 20032314; PMCID: PMC2879949.
  31. Stanton RC. Early administration of enalapril and losartan to patients with type 1 diabetes. Curr Diab Rep. 2009 Dec; 9(6):415-6. PMID: 19954684.
    View in: PubMed
  32. Xu Y, Zhang Z, Hu J, Stillman IE, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J. 2010 Feb; 24(2):609-16. PMID: 19805580; PMCID: PMC2812032.
  33. Jeremias A, Soodini G, Gelfand E, Xu Y, Stanton RC, Horton ES, Cohen DJ. Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus. Heart Int. 2009 Jun 30; 4(1):e7. PMID: 21977284; PMCID: PMC3184698.
  34. Stanton RC. Does blood glucose control improve vascular outcomes in patients with type 2 diabetes? Curr Diab Rep. 2008 Dec; 8(6):461-3. PMID: 18990302.
    View in: PubMed
  35. Stanton RC. Microangiopathy in older patients with diabetes mellitus. Curr Diab Rep. 2007 Dec; 7(6):437-8. PMID: 18255006.
    View in: PubMed
  36. Zhang Z, Zhu B, and Stanton RC. High glucose causes a concurrent increase in NADPH oxidase activity and decrease in glucose 6-phosphate dehydrogenase activity in endothelial cells. J Am Soc Nephrol. 2007.
  37. Stanton RC, Mayer LD, Oriol NE, Treadway KK, Tosteson DC. The mentored clinical casebook project at Harvard Medical School. Acad Med. 2007 May; 82(5):516-20. PMID: 17457078.
    View in: PubMed
  38. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007 Feb; 13(2):189-97. PMID: 17273168; PMCID: PMC3648863.
  39. Stanton RC, Mayer LD, Oriol NE, Treadway KK, Tosteson DC. The mentored clinical casebook. Academic Medicine. 2007; in press.
  40. Williams ME and Stanton RC. Kidney dysfunction in older adults with diabetes. Geriatric Diabetes (Eds. Lipsitz L and Munshi M). 2007.
  41. Stanton R. Clinic versus home blood pressure measurements in patients with CKD. Curr Diab Rep. 2006 Dec; 6(6):453-4. PMID: 17118228.
    View in: PubMed
  42. Stanton RC. Microvascular Disease: Diabetic Nephropathy. The Educational Review Manual in Endocrinology, Diabetes & Metabolism. Focus: Diabetes - 2006 (Eds. Abrahamson M and Ertel NH). 2006; Chapter VIIIA.
  43. Stanton RC. Diabetic Nephropathy and Oxidative Stress. US Endocrine Disease 2006 (Touch Briefings). 2006; (1):65-67.
  44. Stanton RC. Diabetes and the Kidney. Atlas of Diabetes 3rd Edition (Ed. Skyler JS). 2006.
  45. Leopold JA,, Maroni BA, Handy D, Stanton RC, Pitt B, Loscalzo J. Aldosterone decreases glucose 6-phosphate dehydrogenase expression by increased expression of cyclic AMP response element modulator. American Heart Association. 2006.
  46. Leopold JA,, Maroni BA, Handy D, Stanton RC, Pitt B, Loscalzo J. . American Heart Association. Aldosterone antagonism restores vascular reactivity by increasing glucose 6-phosphate dehydrogenase. American Heart Association. 2006.
  47. Stanton RC. Clinical Trials Report. Current Diabetes Reports. 2005; 5(6):443-444.
  48. Xu Y, Osborne B, and Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of protein kinase A which contributes to oxidative stress in rat kidney cortex. Am J Physiol. 2005; 289:F1040-F1047.
  49. Stanton RC. Diabetic Kidney Disease. Time Magazine. 2005.
  50. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol. 2005 Nov; 289(5):F1040-7. PMID: 15956780.
    View in: PubMed
  51. Ficociello LH, Roshan B, Stanton RC, Warram JH, Krolewski AS. Determinants of significant renal function impairment (SRFI) in Type 2 diabetes mellitus (T2DM) in the absence of proteinuria. Journal of the American Society of Nephrology. 2005.
  52. Xu Y, Osborne B, and Stanton RC. Diabetes Leads to Inhibition of Glucose-6-Phosphate Dehydrogenase (G6PD) Via Activation of Protein Kinase A and Decreased G6PD Protein Expression Which Contributes to Increased Oxidative Stress in Rat Kidney Cortex. Diabetes. 2005.
  53. Leopold JA, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone Decreases Glucose-6-Phosphate Dehydrogenase Expression in Vascular Endothelial Cells by Activating Protein Kinase A . American Heart Association. 2005.
  54. Xu Y,Leopold JA, Loscalzo J,and Stanton RC. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Mice have Increased Renal Oxidative Stress and Increased Albuminuria. Journal of the American Society of Nephrology. 2005.
  55. Williams ME and Stanton RC. Diabetic Kidney Disease. Chronic Kidney Disease, Dialysis, and Transplantation (Eds. Pereira BJG, Sayegh MH, and Blake P). 2005; 31-49.
  56. Leopold JA, Handy DE, Stanton RC, Pitt B, Loscalzo J. Vascular Gene Transfer of Glucose-6-Phosphate Dehydrogenase Prevents Aldosterone-mediated Impaired Vascular Reactivity . American Heart Association. 2005.
  57. Williams ME and Stanton RC. Management of Diabetic Kidney Disease. Joslin's Diabetes Mellitus (Eds. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, and Smith RJ). 2005; 925-950.
  58. Jeremias A, Soodini G, Gelfand E, Kirtane AJ, Xu Y, Stanton RC, Horton ES . N-Acetyl-Cysteine Improves C-Reactive Protein levels but not Endothelial Function in Patients with Type II Diabetes Mellitus. American Heart Association. 2005.
  59. Stanton RC. Clinical Trials Report. Current Diabetes Reports. 2004; 4(6):433-434.
  60. Stanton R. Intensive treatment of diabetic nephropathy. Curr Diab Rep. 2004 Dec; 4(6):433-4. PMID: 15539007.
    View in: PubMed
  61. Horal M, Zhang Z, Stanton R, Virkamäki A, Loeken MR. Activation of the hexosamine pathway causes oxidative stress and abnormal embryo gene expression: involvement in diabetic teratogenesis. Birth Defects Res A Clin Mol Teratol. 2004 Aug; 70(8):519-27. PMID: 15329829.
    View in: PubMed
  62. Stanton RC. Diabetic Nephropathy Section for the Virtual Patient. 2004.
  63. Xu Y, Osborne B, and Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase correlating with increased oxidative stress in rat kidney cortex. Diabetes. 2004.
  64. Leopold JA Dam A, Scribner AW, Liao R, Diane E. Handy, DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. American Heart Association Annual Meeting. 2004.
  65. Stanton R. Blood pressure and diabetic nephropathy. Curr Diab Rep. 2003 Dec; 3(6):483-4. PMID: 14611744.
    View in: PubMed
  66. Stanton RC. Clinical Trials Report. Current Diabetes Reports. 2003; 3(6):483-484.
  67. Leopold JA, Walker J, Scribner AW, Voetsch B, Zhang YY, Loscalzo AJ, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem. 2003 Aug 22; 278(34):32100-6. PMID: 12777375.
    View in: PubMed
  68. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol. 2003 Mar 01; 23(3):411-7. PMID: 12615686.
    View in: PubMed
  69. Xu Y, Osborne B, and Stanton RC. Pathogenesis of Diabetic Nephropathy: the Role of Glucose-6-Phosphate Dehydrogenase and Oxidative Stress. J Am Soc Nephrol. 2003; 14:A384.
  70. Leopold, JA, Walker, J, Scribner, AA, Voetsch, B, Zhang YY, Loscalzo AJ, Stanton, RC, Loscalzo, J. Glucose 6-phospate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. Journal of Biological Chemistry. 2003; 278:32100-32106.
  71. Xu Y and Stanton RC. Glucose-6-phosphate dehydrogenase activity is decreased in the aorta of streptozotocin-induced diabetic rats. Diabetes. 2003; A478.
  72. Guo L, Zhang Z, Green K, Stanton RC. Suppression of interleukin-1 beta-induced nitric oxide production in RINm5F cells by inhibition of glucose-6-phosphate dehydrogenase. Biochemistry. 2002 Dec 17; 41(50):14726-33. PMID: 12475221.
    View in: PubMed
  73. Stanton RC. Diabetes and the Kidney. Atlas of Diabetes (Ed. Skyler JS). 2002; 157-169.
  74. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J. 2001 Aug; 15(10):1771-3. PMID: 11481225.
    View in: PubMed
  75. Guo, L, Zhang Z, Green, K, Lovewell G, Stanton RC. Suppression of IL1-beta-induced nitric oxide production in RINm5f cells by inhibition of glucose-6-phosphate dehydrogenase. Mol. Biol. Cell. 2001; 12:419A.
  76. Zhang Z, Gou L, Stanton RC. In contrast to endothelial cells, high glucose increases glucose 6-phosphate dehydrogenase activity and cell hypertrophy/growth in mesangial cells. J Am Soc Nephrol. 2001; 12:A0841.
  77. Zhang Z, Apse K, Stanton RC. Differential effects of high glucose in endothelial cells and renal mesangial cells is mediated, at least in part, by cAMP. FASEB J. 2001; 15(4):A170.
  78. Stanton RC. Joslin's Diabetes Deskbook, Richard S. Beaser and the staff of the Joslin Diabetes Center . 2001.
  79. Zhang Z, Apse K, Pang J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem. 2000 Dec 22; 275(51):40042-7. PMID: 11007790.
    View in: PubMed
  80. Zhang Z, Yu J, Stanton RC. A method for determination of pyridine nucleotides using a single extract. Anal Biochem. 2000 Oct 01; 285(1):163-7. PMID: 10998277.
    View in: PubMed
  81. Tian WN, Braunstein LD, Apse K, Pang J, Rose M, Tian X, Stanton RC. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol. 1999 May; 276(5 Pt 1):C1121-31. PMID: 10329961.
    View in: PubMed
  82. Zhang Z, Apse K, Pang J, Stanton RC. High glucose decreases glucose 6-phosphate dehydrogenase activity and impairs G6PD response to oxidative stress, thus predisposing cells to cell death in cultured bovine aortic endothelial cells. Diabetes (Supplement). 1999; 48:A0546.
  83. Stanton RC. Diabetes and the Kidney. Atlas of Clinical Endocrinology(Kahn CR, editor). 1999; 2:151-161.
  84. Tian WN, Braunstein LD, Pang J, Stuhlmeier KM, Xi QC, Tian X, Stanton RC. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem. 1998 Apr 24; 273(17):10609-17. PMID: 9553122.
    View in: PubMed
  85. Tian W-N, Braunstein L.D., Pang J, Rose M, Stanton RC. Glucose 6-phosphate dehydrogenase (G6PD) plays an important role in cell death. J Am Soc Nephrol. 1998; 9:A2291.
  86. Kopp A, Stanton RC. beta Amyloid does not activate the antioxidant pentose phosphate pathway within the B12 neural cell line. Neuroreport. 1997 Mar 24; 8(5):1197-201. PMID: 9175113.
    View in: PubMed
  87. Tian W-N, Braunstein L.D., Pang J, Stanton RC. Glucose 6-phosphate dehydrogenase (G6PD) plays an important role in cell growth by maintaining cell anchorage. J Am Soc Nephrol. 1997; 8:A1990.
  88. Kopp A, Stanton RC. Amyloid beta cytotoxicity is associated with deficient activation of an oxidative stress regulatory pathway in neural cells. Society of Neuroscience. 1996.
  89. Stanton RC, Braunstein L.D., Tian W-N. Glucose 6-Phosphate Dehydrogenase is a regulator of cell growth. J Am Soc Nephrol. 1996; 7:A2201.
  90. Stanton, RC, Nickeleit V, Mark EJ. Case Records of the Massachusetts General Hospital. A 69-year-old man with progressive renal failure and the abrupt onset of dyspnea. New England Journal of Medicine. 1996; 334:973-979.
  91. Mange KC, Stanton RC. H2O2 inhibits release of 6-phosphogluconate dehydrogenase (6PGD) from permeabilized cells by protein kinase C (PKC) dependent and independent pathways. J. Amer. Soc. Neph. 1995; 6:984A.
  92. Tian W-N, Braunstein LD, and Stanton RC. Dehydroepiandrosterone inhibits peptide growth factor and serum stimulated cell growth, and enhances apoptosis in serum-starved cells. Gordon Conference on Aging. Italy. 1995.
  93. Tian W-N, Bae S, Kopp A, Aldrich H, Stanton RC. Glucose 6-phosphate dehydrogenase (G6PD) localizes around the nucleus in quiescent cells and growth factors stimulate translocation of G6PD to the cytoplasm. 9th International Congress on Signal Transduction and Phosphoproteins. Nashville, TN. 1995.
  94. Tian WN, Pignatare JN, Stanton RC. Signal transduction proteins that associate with the platelet-derived growth factor (PDGF) receptor mediate the PDGF-induced release of glucose-6-phosphate dehydrogenase from permeabilized cells. J Biol Chem. 1994 May 20; 269(20):14798-805. PMID: 8182086.
    View in: PubMed
  95. Mange KC, Stanton RC. Oxidative stress stimulates release of glucose 6-phosphate dehydrogenase (G6PD) and inhibits release of 6-phosphogluconate dehydrogenase (6PGD) in permeabilized cells. J. Amer. Soc. Neph. 1994; 5:723A.
  96. Tian W-N, Pignatare J, and Stanton RC. Autophosphorylation of the platelet-derived growth factor (PDGF) receptor is necessary for the PDGF-induced release of glucose 6-phosphate dehydrogenase (G6PD) from permeabilized cells. J. Amer. Soc. Neph. 1993; 4:503A.
  97. Stanton RC. Redistribution and activation of glucose 6-phosphate dehydrogenase stimulated by peptide growth factors. Gordon Research Conference on Enzyme Organization; Oxnard, Calif. 1993.
  98. Stanton RC, Seifter JL, Boxer DC, Zimmerman E, Cantley LC. Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity. J Biol Chem. 1991 Jul 05; 266(19):12442-8. PMID: 2061319.
    View in: PubMed
  99. Stanton RC, Cantley LC. Characterization of mediators in the growth factor-induced release of bound glucose 6-phosphate dehydrogenase (G6PD) from permeabilized rat kidney cells. Keystone Conference on Signal Transduction; Steamboat Springs, Colorado. 1991.
  100. Stanton RC, Boxer DC, Seifter JL. Expression of Na(+)-H+ exchange and ATP-dependent proton extrusion in growing rat IMCD cells. Am J Physiol. 1990 Mar; 258(3 Pt 1):C416-20. PMID: 2156437.
    View in: PubMed
  101. Stanton RC, Cantley LC. Platelet-derived growth factor and epidermal growth factor cause rapid release of glucose 6-phosphate dehydrogenase in permeabilized cells. Kidney International. 1990; 37:203A.
  102. Stanton RC. Minicases and Tutorial Cases at Harvard Medical School. 1990.
  103. Stanton RC, Zimmerman E, Cantley LC. Sustained elevation of hexose monophosphate shunt in exponentially growing renal and non-renal cell lines: signal transduction mechanisms and growth factor effects. Kidney International. 1989; 35:184A.
  104. Stanton RC, Seifter JL, Brenner BM. Mechanisms of salt and water retention in congestive heart failur. Cardiovascular Reviews and Reports (Supplementum). 1989; 10:5-12.
  105. Stanton RC, Seifter JL. Epidermal growth factor rapidly activates the hexose monophosphate shunt in kidney cells. Am J Physiol. 1988 Feb; 254(2 Pt 1):C267-71. PMID: 3258128.
    View in: PubMed
  106. Stanton RC, Boxer DC, Zimmerman E, Cantley LC, Seifter JL. Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) rapidly activate glucose 6-phosphate dehydrogenase (G6PD) in rat renal cortical cells. Kidney International. 1988; 33:173A.
  107. Stanton RC, Seifter JL. Transport and metabolism in renal cells in culture. Semin Nephrol. 1987 Mar; 7(1):29-36. PMID: 3317629.
    View in: PubMed
  108. Seifter JL, Stanton RC, and Zeidel ML. Ion transport in membrane vesicles. Contemporary Issues in Nephrology, Stein JH, Brenner BM, eds. . 1987; 16:277-297.
  109. Boxer DC, Stanton RC, and Seifter JL. Growth rate of inner medullary collecting duct (IMCD) cells is stimulated by low potassium (LK) and by epidermal growth factor (EGF). Kidney International. 1987; 31:161A.
  110. Stanton RC, Seifter JL, and Brenner BM. Pathogenesis of salt and water retention in congestive heart failure. Contemporary Issues in Nephrology, Stein JH, Brenner BM, eds. . 1987; 16:277-297.
  111. Stanton RC, Seifter JL. Epidermal growth factor (EGF) stimulates growth, Na+/H+ exchange, and hexose monophosphate (HMP) shunt activity in rat proximal tubule cells in primary culture. Kidney International. 1987; 31:182A.
  112. Seifter JL, Stanton RC, and Zeidel ML. Ion transport in membrane vesicles. Contemporary Issues in Nephrology, Stein JH, Brenner BM, eds. . 1987; 15:121-147.
  113. Stanton RC, Mendrick DL, Rennke HG, Seifter JL. Use of monoclonal antibodies to culture rat proximal tubule cells. Am J Physiol. 1986 Nov; 251(5 Pt 1):C780-6. PMID: 3022594.
    View in: PubMed
  114. Stanton RC, Brenner BM. Role of the kidney in congestive heart failure. Acta Med Scand Suppl. 1986; 707:21-5. PMID: 3461687.
    View in: PubMed
  115. Stanton RC, Mendrick DL, Rennke HG, Brenner BM, Seifter JL. Culture of a pure population of proximal tubule (PT) cells using specific monoclonal antibodies to renal brush border membrane proteins. Kidney International. 1986; 29:360A.
  116. Stanton RC, Plant SB, McCarron DA. Verapamil blocks the acute PTH-induced decrease in cAMP in vascular smooth muscle cells. Kidney International. 1985; 27:27A.
  117. Stanton RC, Mendrick DL, Rennke HG, Brenner BM, Seifter JL. Isolation and culture of a pure population of rat proximal tubule cells by immunodissection. NIDDK-NIH meeting on Cell/Tissue Culture in Renal Research in Bethesda, MD. 1985.
  118. Stanton RC, Plant SB, McCarron DA. cAMP response of vascular smooth muscle cells to bovine parathyroid hormone. Am J Physiol. 1984 Dec; 247(6 Pt 1):E822-6. PMID: 6095675.
    View in: PubMed
  119. Stanton RC, Plant SB, McCarron DA. PTH suppression of vascular cAMP: modification by extracellular calcium . IXth International Congress of Nephrology. 1984; 61A.
  120. Stanton RC, Plant SB, McCarron DA. PTH-induced suppression of cAMP content of vascular smooth muscle cells: the influence of trifluoperazine pretreatment . Endocrinology (suppl.). 1983; 112:257A.
  121. McCarron DA, Plant SB, Stanton RC, Ellison DH. Vascular smooth muscle cAMP response to bPTH (1-34) incubation: correlation with hypotensive action . Endocrinology (suppl.). 1982; 110:175A.
  122. Holldobler B, Stanton RC, Markl H. Recruitment and food-retrieving behavior in Novomessor (Formicidae; Hymenoptera). Behavioral Ecology and Sociobiology. 1978; 4:163-181.
  123. Holldobler B, Stanton R, Engel H. A new exocrine gland in Novomessor (Hymenoptera:Formicidae) and its possible significance as a taxonomic character. Psyche. 1976; 83:32-41.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Stanton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_